Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10224144 | 0.91 | KMT2A (0.55) | ACHEKMT2AL3MBTL3L3MBTL1KDM4E | |
| SCHEMBL3455469 | 0.90 | ACHE (0.68) | ACHEKMT2AMEN1EPHX1L3MBTL3 | |
| SCHEMBL22028505 | 0.87 | CHRNB2 (0.56) | ACHEKMT2AMEN1SMN1; SMN2HPGD | |
| SCHEMBL21977131 | 0.85 | MEN1 (0.59) | KMT2AMEN1SMN1; SMN2KDM4ERAB9A | |
| SCHEMBL23421133 | 0.83 | KMT2A (0.47) | ACHEKMT2AMEN1L3MBTL3L3MBTL1 | |
| SCHEMBL433828 | 0.79 | ACHE (0.81) | ACHEKMT2AMEN1EPHX1L3MBTL3 | |
| SCHEMBL18166097 | 0.79 | ACHE (0.81) | ACHEKMT2AMEN1EPHX1L3MBTL3 | |
| SCHEMBL25946040 | 0.79 | ACHE (0.81) | ACHEKMT2AMEN1EPHX1L3MBTL3 | |
| SCHEMBL14600511 | 0.79 | HTT (0.66) | ACHEKMT2AMEN1NPC1RAB9A | |
| SCHEMBL14593573 | 0.78 | CHRNB2 (0.58) | ACHEKMT2AMEN1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200347071-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347071-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | RIPK1, RIPK2, RIPK4 | ACHE 4786/4885KMT2A 3048/4885MEN1 3757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.